Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients

Biomarkers in Medicine

Volumn 8, Issue 2, 2014, Pages 297-306

  Visconti, Laura ^a,b,c,d   Nelissen, Katherine ^a   Deckx, Laura ^b   Akker, Marjan Van Den ^b,c   Adriaensen, Wim ^b   Daniels, Liesbeth ^b   Matheï, Cathy ^b   Linsen, Loes ^a,d   Hellings, Niels ^a   Stinissen, Piet ^a   Buntinx, Frank ^b,c  

^a HASSELT UNIVERSITY   (Belgium)

^b Academic Center for General Practice   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d University Biobank Limburg   (Belgium)

Author keywords

cytokines; mortality; neoplasms; prognosis

Indexed keywords

CYTOKINES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894295332     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.122     Document Type: Review

References (84)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Mathers C, Fat DM, Boerma J. The Global Burden of Disease: 2004 Update. WHO, Switzerland (2008).
3. Anand P, Kunnumakara AB, Sundaram C et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 25(9), 2097-2116 (2008).
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374-1403 (2013).
5. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4(1), 11-22 (2004).
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 420(19), 860-867 (2002).
7. Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117(5), 1175-1183 (2007).
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 140(6), 883-899 (2010).
9. Finn OJ. Cancer immunology. N. Engl. J. Med. 358(25), 2704-2715 (2008).
10. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 20(1), 65-71 (2010).
11. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436-444 (2008).
12. Knpfer H, Prei R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 102(2), 129-135 (2007).
13. Rao V, Dyer C, Jameel J, Drew P, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (review). Oncol. Rep. 15(1), 179-185 (2006).
14. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
15. Heikkil K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 44(7), 937-945 (2008).
16. Apte RN, Voronov E. Is interleukin-1 a good or bad guy in tumor immunobiology and immunotherapy? Immunol. Rev. 222(1), 222-241 (2008).
17. Heikkil K, Harris R, Lowe G et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-Analysis.Cancer Causes Control 20(1), 15-26 (2009).
18. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4(7), 540-550 (2004).
19. Knpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients - a summary of published results. Int. J. Colorectal. Dis. 25(2), 135-140 (2010).
20. Pasche B. Role of transforming growth factor beta in cancer. J. Cell. Physiol. 186(2), 153-168 (2001).
21. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leuk. Biol. 78(5), 1043-1051 (2005).
22. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12(4), 375-391 (2001).
23. Riley R, Sauerbrei W, Altman D. Prognostic markers in cancer: the evolution of evidence from single studies to meta-Analysis, and beyond. Br. J. Cancer 100(8), 1219-1229 (2009).
24. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 323(7306), 224-228 (2001).
25. Smith V, Devane D, Begley CM, Clarke M, Higgins S. A systematic review and quality assessment of systematic reviews of randomised trials of interventions for preventing and treating preterm birth. Eur. J. Obstet. Gynecol. Reprod. Biol. 142(1), 3-11 (2009).
26. Hayden JA, Ct P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann. Intern. Med. 144(6), 427-437 (2006).
27. Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Adv. Otorhinolaryngol. 62, 184-200 (2005).
28. Hollnder N, Sauerbrei W. On statistical approaches for the multivariable analysis of prognostic marker studies. In: Advances in Statistical Methods for the Health Sciences. Springer, Germany, 19-38 (2007).
29. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J. Natl Cancer. Inst. 86(11), 829-835 (1994).
30. Kyzas PA, Denaxa-Kyza D, Ioannidis J. Almost all articles on cancer prognostic markers report statistically significant results. Eur. J. Cancer 43(17), 2559-2579 (2007).
31. Kyzas PA, Loizou KT, Ioannidis J. Selective reporting biases in cancer prognostic factor studies. J. Natl Cancer. Inst. 97(14), 1043-1055 (2005).
32. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for action. Clin. Chem. 54(7), 1101-1103 (2008).
33. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J. Natl Cancer. Inst. 99(3), 236-243 (2007).
34. Simon R, Altman D. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 69(6), 979-985 (1994).
35. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. In: Prognostic Variables in Node-Negative and Node-Positive Breast Cancer. Springer, Germany, 379-393 (1998).
36. Riley R, Abrams K, Sutton A et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br. J. Cancer 88(8), 1191-1198 (2003).
37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Int. J. Surg. 8(5), 336-341 (2010).
38. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151(4), W65-W94 (2009).
39. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93(4), 387-391 (2005).
40. Riley RD, Hayden JA, Steyerberg EW et al. Prognosis research strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 10(2), e1001380 (2013).
41. Galizia G, Orditura M, Romano C et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol. 102(2), 169-178 (2002).
42. Galizia G, Lieto E, De Vita F et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J. Interferon Cytokine Res. 22(4), 473-482 (2002).
43. Dosquet C, Coudert M-C, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res. 3(12), 2451-2458 (1997).
44. Dosquet C, Schaetz A, Faucher C et al. Tumour necrosis factor-A, interleukin-1b and interleukin-6 in patients with renal cell carcinoma. Eur. J. Cancer 30(2), 162-167 (1994).
45. Sarris AH, Kliche K-O, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkins disease and are associated with inferior failure-free survival. Ann. Oncol. 10(4), 433-440 (1999).
46. Duffy SA, Taylor JM, Terrell JE et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113(4), 750-757 (2008).
47. Liao W-C, Lin J-T, Wu C-Y et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin. Cancer Res. 14(2), 428-434 (2008).
48. Di Nisio M, Niers TM, Reitsma PH, Buller HR. Plasma cytokine and P-selectin levels in advanced malignancy. Cancer 104(10), 2275-2281 (2005).
49. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-A correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 90(12), 2312-2316 (2004).
50. Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais dImmunotherapie. J. Clin. Oncol. 22(12), 2371-2378 (2004).
51. Kuo CP, Wu CL, Ho HT, Chen C, Liu SI, Lu YT. Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy. Clin. Microbiol. Infect. 14(3), 221-227 (2008).
52. Desborough J. The stress response to trauma and surgery. Br. J. Anaesth. 85(1), 109-117 (2000).
53. Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit. Care 6(4), 298-305 (2002).
54. Myers JS, Pierce J, Pazdernik T. Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment. Oncol. Nurs. Forum 35(6), 916-920 (2008).
55. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 127(2), 117-126 (2000).
56. Hensler T, Hecker H, Heeg K et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect. Immun. 65(6), 2283-2291 (1997).
57. Park SK, Wallace H, Brody J, Blakemore W. Immunosuppressive effect of surgery. Lancet 297(7689), 53-55 (1971).
58. Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine 43(3), 336-341 (2008).
59. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144(6), 2195-2200 (2003).
60. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler. Thromb. Vasc. Biol. 22(10), 1668-1673 (2002).
61. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9(7), 414-417 (2001).
62. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-Analysis of prospective observational studies. Lancet 371(9612), 569-578 (2008).
63. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630), 1134 (2007).
64. Martin B, Paesmans M, Berghmans T et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-Analysis. Br. J. Cancer 89(1), 55-64 (2003).
65. Altman D, De Stavola B, Love S, Stepniewska K. Review of survival analyses published in cancer journals. Br. J. Cancer 72(2), 511-518 (1995).
66. Burton A, Altman D. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br. J. Cancer 91(1), 4-8 (2004).
67. Holland NT, Smith MT, Eskenazi B, Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat. Res. 543(3), 217-234 (2003).
68. Betsou F, Lehmann S, Ashton G et al. Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol. Biomark. Prev. 19(4), 1004-1011 (2010).
69. Lehmann S, Guadagni F, Moore H et al. Standard preanalytical coding for biospecimens: review and implementation of the sample PREanalytical code (SPREC). Biopreserv. Biobank. 10(4), 366-374 (2012).
70. Plebani M. Quality indicators to detect pre-Analytical errors in laboratory testing. Clin. Biochem. Rev. 33(3), 85-88 (2012).
71. Baune BT, Rothermundt M, Ladwig KH, Meisinger C, Berger K. Systemic inflammation (interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO study. Age 33(2), 209-217 (2011).
72. Benoy IH, Salgado R, Van Dam P et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10(21), 7157-7162 (2004).
73. Chang KP, Chang YT, Wu CC et al. Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 33(6), 886-897 (2011).
74. Chung Y-C, Chang Y-F. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 50(54), 1910-1913 (2003).
75. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma. Cancer 101(12), 2727-2736 (2004).
76. Faderl S, Do K-A, Johnson MM et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106(13), 4303-4307 (2005).
77. Kaminska J, Nowacki M, Kowalska M et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - an independent prognostic factor. Tumor Biol. 26(4), 186-194 (2005).
78. Martn F, Santolaria F, Batista N et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11(1), 80-86 (1999).
79. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkins disease and with B symptoms. Cancer Res. 53(9), 2118-2122 (1993).
80. Mustea A, Pirvulescu C, Knsgen D et al. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 42(1), 77-84 (2008).
81. Orditura M, De Vita F, Catalano G et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J. Interferon Cytokine Res. 22(11), 1129-1135 (2002).
82. Ren Y, Poon RT-P, Tsui H-T et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma correlations with clinicopathological features and prognosis. Clin. Cancer Res. 9(16), 5996-6001 (2003).
83. Wierda WG, Johnson MM, Do KA et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br. J. Haematol. 120(3), 452-456 (2003).
84. Zeimet AG, Widschwendter M, Knabbe C et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J. Clin. Oncol. 16(5), 1861-1868 (1998).